Permanent up-regulation of regulatory T-lymphocytes in patients with head and neck cancer

ANNE K. SCHOTT*, RALPH PRIES* and BARBARA WOLLENBERG

Department of Otorhinolaryngology, University of Schleswig-Holstein Campus Lübeck, D-23538 Lübeck, Germany

Received December 3, 2009; Accepted January 26, 2010

DOI: 10.3892/ijmm_00000436

Abstract. Various immune functions of different types of immune cells are strongly impaired in patients with head and neck squamous cell carcinoma (HNSCC). Regulatory T-lymphocyte cells (Tregs) have been suggested to be involved in the immunomodulation of immune responses and contribute to HNSCC progression and immune escape. ‘Naturally’ occurring CD4+CD25+ Tregs represent a small fraction within the different subsets of regulatory T cells, which are known to inhibit numerous immune functions of different types of immune cells. In this study, the cellular ratio of CD4+CD25high Tregs to the entire population of CD4+ T-lymphocytes was analyzed with respect to different stages of tumor progression and disease. Our data indicate a significantly high increased abundance of CD4+CD25highCD127low Tregs in the peripheral blood of patients with HNSCC, which in addition show modulated expression levels of various functional proteins. Surprisingly, increased Treg levels were found even in patients with no active disease several years after tumor resection, with no significant correlation to the individual tumor stage. Additionally, increased levels of chemokine CCL22, which mediates migration of Tregs to the tumor, and upregulation of the corresponding receptor protein CCR4 were observed in HNSCC. Our data strongly suggest that HNSCC leads to a permanent shift of Treg levels with hardly recognizable recovery rates.

Introduction

Head and neck squamous cell carcinoma (HNSCC) is one of the most common tumors and standard treatment has only slightly improved the 5-year survival rate of patients with HNSCC over the last 40 years (1-6). Different studies have shown that the HNSCC micro-environment strongly impairs different types of immune cells such as natural killer (NK) cells (7), monocytes (8) and T-lymphocytes (9). It has been suggested that regulatory T-lymphocytes (Tregs) play an important role in the suppression of anti-tumor immune responses and thus strongly participate in the immune escape process (10-19).

Tregs are divided into several subtypes, the so called ‘naturally’ occurring CD4+CD25+ Tregs and ‘induced’ or ‘adaptive’ Tregs, all of which are different in development, phenotype, cytokine secretion and immune function (20,21). Naturally occurring CD4+ Tregs constitute a small fraction of the overall CD4+ T cell population and constitutively co-express CD25, a high affinity IL-2 receptor α-subunit, on a high level (CD25high)(22).

Natural CD4+CD25high Tregs arise in the thymus as a sub-population of T-lymphocytes by the escape from apoptotic death during negative selection (23) and high-avidity interactions of their T cell receptors with self-peptides presented by MHC class II molecules expressed on thymic stroma cells (24,25). Tregs appear to inhibit a variety of immune functions, such as the proliferation and cytokine secretion of CD4+ T cells as well as the lytic granule release by CD8+ effector cells (12,26). Moreover, Tregs modulate the function and maturation of dendritic cells, monocytes and B-lymphocytes and the cytotoxic effects of NK cells (12,27,28). Besides playing an important role in the regulation of immunotolerance and the prevention of autoimmune diseases (29), elevated proportions of regulatory T cells were found in different types of cancers, such as lung, breast (30), prostate cancer (31) and B-cell non Hodgkin lymphoma (32), and also in HNSCC (33). Furthermore, Tregs have been shown to be associated with a reduced survival in patients with ovarian carcinoma (34).

It has been suggested, that tumor-related factors induce and expand the accumulation of regulatory T cells in cancer-bearing hosts (35). According to Curiel et al (34), ovarian tumor cells and microenvironmental macrophages produce CCL22/macrophage derived chemokine (MDC), a chemokine that induces the migration of regulatory T cells through corresponding CCL22 chemokine receptor CCR4 to tumor sites and impair anti-tumor immune responses.

Recent studies have suggested that CD4+CD25+ T cells are subdivided into suppressive CD4+CD25high Treg cells as well as CD4+CD25low T cells, which are non-suppressive, antigen-experienced activated CD4+ T cells (36). In addition, the α-chain of the IL-7 receptor (CD127) is supposed to be a specific marker protein for suppressive Tregs, namely CD4+CD25high CD127low (37). It was recently demonstrated that Tregs are...
characterized by low levels of CD127, which together with a high expression of CD25 (CD25 high) helps distinguish Tregs from activated CD4+ T-lymphocytes.

Our investigations demonstrate a strong and permanent increased ratio of circulating CD4+CD25highCD127low Tregs within the entire population of CD4+ T-lymphocytes through HNSCC, which was found even in patients with no active disease after several years.

Materials and methods

Preparation of peripheral blood samples. After written informed consent, peripheral blood samples were taken from healthy blood donors and patients with HNSCC. All HNSCC tumor patients had histologically proven HNSCC, either at the time of blood draw or before (summarized in Table I). At the time of blood withdrawal, 16 patients had active disease (AD; presurgery) and 16 patients showed no evidence of disease anymore (NED; post-surgery).

As healthy controls, human Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats provided by the blood bank of the University of Lübeck, Germany. Blood donors were 18-65-year-old healthy men and women who were tested negative for HIV and hepatitis B and C viruses. Serum, used for the CCL22-ELISA, was taken from 21 voluntary donors. Patient characteristics and disease classification are

Table I. Clinicopathologic features (sex, age, tumor site, TNM-stage, post-surgery since) of patients with HNSCC included in the study.

A. Sixteen presurgery patients with active disease characterized by sex, age, tumor site and TNM-stage

<table>
<thead>
<tr>
<th>Sample no.</th>
<th>Sex</th>
<th>Age</th>
<th>Tumor site</th>
<th>TNM-stage</th>
</tr>
</thead>
<tbody>
<tr>
<td>TB479</td>
<td>m</td>
<td>43</td>
<td>epipharynx</td>
<td>cT4bcN3cM0</td>
</tr>
<tr>
<td>TB527</td>
<td>f</td>
<td>66</td>
<td>oropharynx (relapse)</td>
<td>pT3N0cM0</td>
</tr>
<tr>
<td>TB530</td>
<td>m</td>
<td>49</td>
<td>hypopharynx (relapse)</td>
<td>pT3pN2bcM0</td>
</tr>
<tr>
<td>TB533</td>
<td>m</td>
<td>55</td>
<td>hypopharynx/larynx</td>
<td>pT4apN1cM1</td>
</tr>
<tr>
<td>TB534</td>
<td>m</td>
<td>69</td>
<td>hypopharynx/larynx</td>
<td>cT3-4cN2acM1</td>
</tr>
<tr>
<td>TB535</td>
<td>m</td>
<td>76</td>
<td>larynx (relapse)</td>
<td>pT3pN0cMx</td>
</tr>
<tr>
<td>TB536</td>
<td>m</td>
<td>71</td>
<td>oropharynx</td>
<td>cT3cN2acM0</td>
</tr>
<tr>
<td>TB537</td>
<td>m</td>
<td>64</td>
<td>larynx/hypopharynx</td>
<td>pT4pN2bcM0</td>
</tr>
<tr>
<td>TB538</td>
<td>f</td>
<td>57</td>
<td>hypopharynx</td>
<td>cT4acN2ccM1</td>
</tr>
<tr>
<td>TB539</td>
<td>m</td>
<td>81</td>
<td>oral cavity</td>
<td>cT3cN2cM0</td>
</tr>
<tr>
<td>TB541</td>
<td>m</td>
<td>56</td>
<td>vocal cord right</td>
<td>pT2cN0cM0</td>
</tr>
<tr>
<td>TB543</td>
<td>m</td>
<td>64</td>
<td>larynx</td>
<td>pT3pN0cM0</td>
</tr>
<tr>
<td>TB544</td>
<td>m</td>
<td>77</td>
<td>larynx (relapse)</td>
<td>cT4cN2bcM1</td>
</tr>
<tr>
<td>TB545</td>
<td>m</td>
<td>41</td>
<td>larynx</td>
<td>pT4apN2bcM0</td>
</tr>
<tr>
<td>TB546</td>
<td>m</td>
<td>44</td>
<td>CUP</td>
<td>cT4bcN3cM0</td>
</tr>
<tr>
<td>TB782</td>
<td>m</td>
<td>61</td>
<td>oropharynx</td>
<td>pT4apN2ccM1</td>
</tr>
</tbody>
</table>

B. Fourteen postsurgery patients with no evidence of disease having received curative therapies; accessory specification of the post-surgery time frame

<table>
<thead>
<tr>
<th>Sample no.</th>
<th>Sex</th>
<th>Age</th>
<th>Tumor side</th>
<th>TNM-stage</th>
<th>Post-surgery since</th>
</tr>
</thead>
<tbody>
<tr>
<td>TB525</td>
<td>m</td>
<td>46</td>
<td>oral cavity</td>
<td>pT1cN0pMx</td>
<td>3.0 years</td>
</tr>
<tr>
<td>TB526</td>
<td>m</td>
<td>67</td>
<td>hypopharynx</td>
<td>pT3pN3cM0</td>
<td>4.0 years</td>
</tr>
<tr>
<td>TB528</td>
<td>m</td>
<td>57</td>
<td>hypopharynx</td>
<td>pT4pN2bcM0</td>
<td>5.0 years</td>
</tr>
<tr>
<td>TB529</td>
<td>m</td>
<td>49</td>
<td>oral cavity</td>
<td>pT1pN0cM0</td>
<td>18.0 days</td>
</tr>
<tr>
<td>TB531</td>
<td>m</td>
<td>55</td>
<td>nasal cavity</td>
<td>pT1cN0cM0</td>
<td>36.0 days</td>
</tr>
<tr>
<td>TB532</td>
<td>f</td>
<td>78</td>
<td>Gl. parotis</td>
<td>pT3pN0cM0</td>
<td>10.0 days</td>
</tr>
<tr>
<td>TB768</td>
<td>m</td>
<td>61</td>
<td>larynx</td>
<td>pT1cN0cM0</td>
<td>1.5 years</td>
</tr>
<tr>
<td>TB777</td>
<td>m</td>
<td>65</td>
<td>larynx/hypopharynx</td>
<td>cT3cN2bcM0</td>
<td>3.0 years</td>
</tr>
<tr>
<td>TB778</td>
<td>m</td>
<td>44</td>
<td>larynx</td>
<td>pT2cN0cM0</td>
<td>7.0 months</td>
</tr>
<tr>
<td>TB779</td>
<td>m</td>
<td>53</td>
<td>larynx/hypopharynx</td>
<td>pT4apN1cM0</td>
<td>10.0 months</td>
</tr>
<tr>
<td>TB780</td>
<td>m</td>
<td>67</td>
<td>larynx</td>
<td>pT2pN1cM0</td>
<td>3.0 years</td>
</tr>
<tr>
<td>TB781</td>
<td>m</td>
<td>57</td>
<td>oropharynx</td>
<td>pT1pN2acM0</td>
<td>1.0 year</td>
</tr>
<tr>
<td>TB783</td>
<td>m</td>
<td>69</td>
<td>hypopharynx</td>
<td>pT2pN0cM0</td>
<td>2.0 years</td>
</tr>
<tr>
<td>TB784</td>
<td>m</td>
<td>74</td>
<td>larynx</td>
<td>pT4pN0cM0</td>
<td>9.0 years</td>
</tr>
</tbody>
</table>

characterized by low levels of CD127, which together with a high expression of CD25 (CD25 high) helps distinguish Tregs from activated CD4+ T-lymphocytes.

Our investigations demonstrate a strong and permanent increased ratio of circulating CD4+CD25highCD127low Tregs within the entire population of CD4+ T-lymphocytes through HNSCC, which was found even in patients with no active disease after several years.
sodium pyruvate and incubated in cell culture flasks with 37˚C supplemented with 10% FCS, 1 mM glutamine and 0.1 mM sodium pyruvate and incubated in cell culture flasks with 37°C.

**Cell culture.** Permanent HNSCC cell lines BHY (DSMZ Germany) (38), PCI-1 and PCI-13 (generously provided by T.L. Whiteside, Pittsburgh Cancer Institute) were cultured in DMEM-medium (Dulbecco's Modified Eagle Medium, Gibco) supplemented with 10% FCS, 1 mM glutamine and 0.1 mM sodium pyruvate and incubated in cell culture flasks with 37°C and 5% CO2 in an incubator.

**Flow cytometry.** Surface antigen staining was performed as described previously (39). Cells were stained with peridinin chlorophyll (CD4-PerCP, BD Biosciences), allophycocyanin (CD25-APC, eBioscience), fluorescein-5-isothiocyanate (CD25-FITC, eBioscience), phycoerythrin-Cy7 (CD45RA-PE-CY7, BD Biosciences), GITR-FITC (eBioscience), CD152, phycoerythrin (CTLA-4-PE, BD Biosciences), phycoerythrin (CD122-PE, BD Biosciences), phycoerythrin-Cy7 (CCR7-PE-CY7, BD Biosciences), phycoerythrin-Cy5 (CCR4-PE-CY7, BD Biosciences), fluorescein-5-isothiocyanate (CD62L-FITC, BD Biosciences) antibodies as specified in figure legends. For intracellular staining of FOXP3 and CTLA-4 (CD152), PE anti-human FOXP3 Flow Kit from BioLegend was used. For measuring of intracellular CCL22, cells were permeabilized using saponin buffer (PBS, 0.1% FCS and 1 M HEPES), stained with monoclonal anti-human CCL22/MDC antibody (R&D Systems) and the corresponding secondary antibody PE goat anti-mouse Ig (BD Biosciences) or APC goat anti-mouse Ig (BD Biosciences). Propidium-iodide was used to determine dead cells. Isotype control monoclonal antibodies were used to estimate the non-specific binding of target primary antibodies to antigens. Samples were analyzed on a FACSCanto (BD Biosciences, Heidelberg, Germany) and data acquisition was performed using the FACSDiva software (BD Biosciences).

**Cytokine analysis.** The Enzyme-linked immunosorbent assay (ELISA) was used for determination of CCL22/MDC levels in supernatants according to the manufacturer's instructions (Quantikine Human MDC, R&D Systems). This cytokine assay allows the multiplexed quantitative measurement of multiple cytokines in a single small volume of cell culture supernatant or serum. The minimum detectable dose of MDC is typically <62.5 pg/ml. The cytokine array was analyzed by a specialized microplate reader (Microplate Manager 5.2, Bio-Rad) set to 450 nm and revealed data were calculated using the Microplate spectrophotometer (Microplate Manager software, Bio-Rad). Data were expressed as the means ±SD.

**Protein analysis.** CCL22 protein expression was analyzed in the lysate of PCI-1, PCI-13, BHY (see above), adenoid vegetations (H437), human tongue squamous cell carcinoma (Cal27) and HaCaT. HaCaT is a permanent epithelial (immortalized keratinocyte cell line) cell line from adult human skin and serves as a positive control for CCL22 production (40). The adenoid vegetations (H437) were used as a negative control. Cell extracts were prepared and solubilized and protein concentrations were determined using the Bio-Rad protein assay kit (Bio-Rad GmbH, Munich, Germany) with bovine serum albumin (BSA) as a standard. Aliquots of protein extracts (60 μg) were run on SDS-PAGE and were then transferred onto a nitrocellulose membrane. Blots were decorated with monoclonal anti-human CCL22/MDC antibody (R&D Systems) and mouse anti-ß-actin antibody as loading control (mAbcam).

**Statistical analysis.** Statistical analysis was performed using the SPSS 12.0 program (SPSS Inc., Chicago, USA), SigmaPlot 10.0 (Systat Software Inc) and Office 2003 (Microsoft Corporation, Redmont, USA). Data are expressed as mean ±SD resulting from at least four independent experiments. The achieved results were tested by means of Kolmogorov-Smirnov-test regarding normal distribution. The significance of the results was determined using the Student t-test for independent samples (highly significant, p<0.01; significant, 0.01>p<0.05; trend, 0.05>p<0.1) otherwise statistical analysis was performed using the Mann-Whitney-U-test.

**Results**

**Increased ratio of Tregs within CD4+ T cells in HNSCC patients.** The abundance of circulating lymphocytes, CD4+, CD4+CD25–, CD4+CD25high/CD127low–, and CD4+CD25low/CD127high-T cells in the peripheral blood of patients with HNSCC was analyzed using flow cytometry. The presented study included 25 patients with HNSCC and 27 healthy controls, which are summarized in Table I.

 Patients with HNSCC showed a highly significant increase of CD4+CD25high/CD127low T-lymphocytes in comparison with healthy controls (3.4±2.5% in HNSCC vs. 1.8±1.7% in NC; p<0.01) (Fig. 1A and B). Human CD4+CD25+ cells are subdivided in suppressor CD4+CD25high and CD4+CD25low T cells, which are non-suppressive, antigen-experienced activated CD4+ T cells (36). A low expression of CD127 (CD127low) together with a high expression of CD25 (CD25high) is supposed to be specific for suppressive Treg cells (37). Our data show that up to 98% of CD4+CD25+ T cells are non-suppressive CD4+CD25low and normal controls displayed significantly higher percentages of CD4+CD25low/CD127high T cells relative to HNSCC patients (98.2±1.7% in NC vs. 96.6±2.5% in HNSCC; p<0.01). In the TNM-stages, no significant correlation between tumor stage and the level of circulating Treg cells was observed in the peripheral blood of HNSCC tumor patients.

**Phenotypic analysis of CD4+ T cell subsets.** Circulating CD4+CD25low/CD127low lymphocytes from HNSCC patients and healthy controls were analyzed concerning the expression of functional proteins forhead box P3 (FoxP3), membrane glucocorticoid-induced tumor-necrosis factor receptor family-related gene (GITR), immunoregulatory protein cytolytic T-lymphocyte-associated antigen 4 protein or CD152 (CTLA-4), chemokine receptors CCR7 and CCR4, the ‘homing receptor’ CD62L, CD45RA and the β-chain of the IL-2-receptor CD122. In patients with HNSCC 48.3% of the analyzed CD4+CD25low/CD127low Treg cells expressed the transcriptional activator
protein FoxP3, 22.7% expressed GITR, 68.6% CTLA-4, 54.8% expressed CCR7, 86.9% CCR4, 78.5% CD62L, 51.4% CD45RA and 34.96% expressed CD122. Comparing the percentages of the different markers on CD4+CD25highCD127low Treg cells in HNSCC patients with healthy controls, there existed no significant difference in the expression of GITR, CTLA-4, CD45RA, CCR4 and CD62L. However, CCR7 showed a tendency (0.05<p<0.1) for a higher expression of CD4+CD25highCD127low Treg cells in HNSCC patients.

On the other hand, the amount of CD122 (interleukin-2, IL-2/IL-15 receptor β-chain), which plays a role in regulating normal lymphocyte development in vivo, expressing CD4+CD25lowCD127low Treg cells were highly significantly increased in healthy controls relative to HNSCC patients (60.8 vs. 35%; p<0.01). Consistent with the significant increase of CD4+CD25highCD127low Treg cells in the peripheral blood of patients with HNSCC relative to healthy controls, our data displayed that the amount in percentage of Foxp3 (48.3 vs. 70% SCHOTT et al: Tregs IN HEAD AND NECK CANCER

Figure 1. Increase of CD4+CD25high Treg cells in peripheral blood of HNSCC patients compared with healthy controls. The abundance of circulating CD4+CD25high Treg cells in PBMC of 25 HNSCC tumor patients (TB) and 27 healthy controls (H) was analyzed by flow cytometry and compared to the overall level (%) of CD4+ T-lymphocytes. (A) Red line, average of CD4+CD25high Treg within CD4+ T cells in patients with HNSCC; green line, average of CD4+CD25high Treg within CD4+ T cells in normal controls. Fourteen HNSCC tumor patients are patients with an active disease; 11 patients marked with ‘ps’ are patients showing no evidence of disease (post-surgery) and oncolgical treatment of the tumor was carried out between 10 days and 9 years ago. Our data demonstrate strongly increased ratios of CD4+CD25high Treg cells to CD4+ T lymphocytes in the peripheral blood of patients with HNSCC compared to healthy donors with individually deviating levels. These findings are independent of activity of disease. Patients with HNSCC, TB525-TB539, TB541, TB543-TB546, TB768, TH777-TH779, TB784; normal controls: H1-H20, H25, H28, H30-H34. (B) Example of enrichment in CD4+CD25+, CD4+CD25high and CD4+CD25low Treg cells in PBMCs of a single patient with HNSCC (TB784) in comparison with a healthy control (H30). The PBMCs of the HNSCC patient were found to contain 28.6% CD4+CD25high Treg cells, that consist of 6% CD4+CD25high and 94% CD4+CD25low Treg cells relative to 12% CD4+CD25high Treg cells, 1.5% CD4+CD25high and 98.5% CD4+CD25low Treg cells in the normal control.
expressing CD4+CD25highCD127low Treg cells were also highly significantly increased in these patients (Fig. 2). The transcription factor Foxp3 has been shown to be critical for the development and function of CD4+CD25high regulatory T cells. However, recently FOXP3 expression has been shown to be induced upon activation of human CD4+ T cells (41) and the expression is not supposed to be restricted to Treg cells. Hence we analyzed a possible expression of Foxp3 in lymphocytes, CD4+, CD4+CD25+ and CD4+CD25lowCD127high T cells (Fig. 2). We showed that all analyzed cells displayed an expression of Foxp3. However, the percentage of Foxp3 expression was again significantly higher in patients with HNSCC (Fig. 2B).

HNSCC induces a permanent shift of Treg abundance. Analyzed patients with HNSCC were subdivided into patients with an active tumor disease (AD) (n=14) and postsurgery patients (n=11) with no evidence of an active disease (NED) after oncologic therapy. Oncological treatment (surgery ±radiochemotherapy) of the tumor was carried out between 10 days and 9 years ago.

Surprisingly, the mean ratio of CD4+CD25highFoxp3+ Treg cells to the total of peripheral blood CD4+ T cells was still significantly increased in all analyzed samples, even up to 9 years after active disease and oncologic therapy (Fig. 1A). Our data demonstrate that HNSCC leads to a permanent shift of the Treg abundance with hardly recognizable recovery rates.

Even though we found no difference in the mean ratio of CD4+CD25highCD127low Treg cells between patients with AD and NED, we noted that the percentage of GITR and CCR4 expressing Treg cells were significantly higher among PBMCs from HNSCC patients with an active stage of disease (AD). In addition the expression levels of CCR4 and GITR were significantly higher on the surface of single CD4+CD25highCD127low Treg cells in patients with active disease, declared by the mean fluorescence intensity measured by flow cytometry. Moreover, our data displayed, that patients before being treated with an oncological therapy show significantly higher percentages of GITR and Foxp3 expressing lymphocytes, CD4+ and CD4+CD25low T cells.

CCL22 as a chemoattractant in HNSCC. The ability of HNSCC to autonomously produce CCL22 was investigated using permanent HNSCC cell lines PCI-1 and PCI-13. Flow cytometric analyses demonstrate a significant production of CCL22 (Fig. 3). Furthermore, our data displayed an extracellular expression of CCL22 on the surface of the analyzed HNSCC cell lines, which is highly significantly lower (p<0.01) than the detected intracellular expression (Fig. 3A).

In addition, the CCL22 expression was analyzed in protein lysates of permanent HNSCC cell lines PCI-1, BHY, adenoid vegetations (H437) (Fig. 3B), as well as PCI-13, Cal 27 and HaCaT by Western blotting (Fig. 3B). Fig. 3B demonstrates that CCL22 can be detected in all analyzed permanent cell lines with similar expression levels. The adenoid vegetations (H437) served as a negative control and showed no production of CCL22. The human keratinocyte cell line HaCaT was used as a positive control as described in previous studies (40,42). To evaluate the relationship between the level of CCL22 and the frequencies of regulatory CD4+CD25high T cells in patients with HNSCC (Fig. 2B).
HNSCC patients, we examined the expression of chemokine CCL22/MDC in the serum of 19 tumor patients and 21 healthy blood donors, which are summarized in Table I. Our data demonstrate that there are no significant differences of the CCL22 levels in the peripheral blood of tumor patients compared to healthy donors, but only individual deviations. Furthermore, our data show no correlation between HNSCC tumor stage (TNM) and the level of CCL22 in the peripheral blood (Fig. 4).

Since IFN-γ is known to suppress constitutive expression of CCL22 in mature macrophages and dendritic cells (43), we analyzed its influence on the CCL22 production in HNSCC. Therefore, permanent HNSCC cell lines were cultivated in 5 ml DMEM-medium with 2 μl (4,000 pg/ml) recombinant human IFN-γ for 12, 48 or 72 h, respectively. Cells were analyzed by flow cytometry and the level of CCL22 before and after incubation with INF-γ was declared in Mean Fluorescence Intensity (MFI), which is an admeasurement for adhesion of antibodies and for the expression and production of CCL22. The decrease in the CCL22 level after incubation with INF-γ was specified in percent (Fig. 5). Our data indicate that INF-γ leads to a reduced expression of CCL22 in HNSCC.

Discussion

In recent years, a variety of immunoregulatory functions and different subsets of Tregs in cancer patients have been described and the concept has emerged that peripheral tolerance to tumors is maintained and enhanced by Tregs (14,19,22,44). In this work we demonstrate that malignant head and neck
cancer strongly modulates the abundance of CD4+CD25high regulatory T cells in the peripheral blood of HNSCC tumor patients for a long time period. We show that circulating CD4+CD25high Tregs in HNSCC patients possess a characteristic phenotype determining their regulatory function such as CD25+, transcriptional activator Foxp3+, CTLA-4+ (cytotoxic T-lymphocyte-associated antigen 4; CD152), glucocorticoid-induced tumor necrosis factor receptor (GITR+), CD45RA+, the chemokine receptors CCR7+ and CCR4+ and the ‘homing’ receptor CD62L+. Significantly increased levels not only of CD4+CD25highFoxp3+ Treg cells, but also of Foxp3 expressing lymphocytes, CD4+ T lymphocytes, CD4+CD25+ and CD4+CD25lowCD127 high T cells were found in patients with HNSCC compared to healthy controls. In different solid tumors, the accumulation of Foxp3+ Tregs has been associated with reduced survival rates of tumor patients (34,45-47). Hence the greater number of Foxp3 expressing Treg cells may reflect the increased suppressive activity seen in patients with HNSCC (33). However, it is important to mention that according to Hori et al (48) the expression of Foxp3 on T-lymphocytes does not necessarily implicate suppressive abilities.

Our data demonstrate the long-term character of tumor modulated Treg abundance and the CCL22-level in patients with HNSCC. These data are in accordance with other recent studies, which implicate that malignant tumors, independently from the disease stage, site or nodal involvement, have a strong impact on the homeostasis of lymphocytes long after the tumor is removed, even in the absence of any chemo- or radiotherapeutic treatments (9,49). Even though we found no difference in the mean ratio of CD4+CD25highCD127low Treg cells between patients with AD and NED, we noted however that levels of GITR and CCR4 expressing Treg cells were significantly higher among PBMCs from HNSCC patients with an active stage of disease (AD). GITR as well as CCR4 can be upregulated on T cells upon activation and TCR and CD28 engagement (50). The increased expression of the receptor on single Treg cells in patients with an active disease...
might be consistent with a higher response of Treg cells to the chemotractant CCL22. Furthermore, the fact that patients with active disease show a significant increase of GITR expressing T cells is of special interest, because GITR is a typical Treg surface marker, that is supposed to abrogate Treg cell mediated suppression upon stimulation of GITR (51). But according to a previous (52) while GITR triggering weakens suppressor activity, it can induce Treg proliferation and expansion (53,54). Furthermore, after GITR co-stimulation, Treg cells are supposed to regain their suppressive activity. This fact can imply, that the final outcome of a transient inhibition by GITR of suppressive activity and an increase of Treg proliferation could result in an overall increase of suppressor activity (52).

CCL22 binds to and activates the G-protein-coupled CCR4, a CC chemokine receptor, that is primarily expressed by CD4+ and CD8+ lymphocytes with a Th2 phenotype and CD25+ regulatory T cells (55-59), but also by natural killer cells, dendritic cells and macrophages (60). CCR4 is supposed to be important for regulating immune balance (61). Curie et al (34) have shown, that tumor cells and microenvironmental macrophages in ovarian carcinoma produce CCL22, which mediates migration of regulatory T cells to the tumor. We showed in our study, that HNSCC is also able to autonomously produce CCL22.

Our data demonstrate that IFN-γ is able to downregulate CCL22 production in HNSCC. Interferon-γ is a representative of Th1 cytokines (62) and it is secreted by Th1 cells, dendritic cells and natural killer cells. INF-γ has antiviral, immunoregulatory and anti-tumor properties. Immune responses in HNSCC tumor patients have been shown to be biased toward the secretion of Th2 cytokines, which prevent effective anti-tumor Th1 immune responses and so facilitate the production of CCL22 and in succession the recruitment of Tregs to tumor sites (63,64).

In conclusion, the increase of regulatory T cells in HNSCC tumor patients might stand for a reduced anti-tumor immunity and therefore contribute to an optimized tumor immune evasion and progression or recurrence of head and neck cancer.

Acknowledgements

We are grateful to Eveline Szymanski and Brigitte Wollmann for skillful support in several parts of this work and all members of the Department of Otorhinolaryngology for helpful discussions and a comfortable atmosphere. Furthermore, we thank T.L. Whiteside (Pittsburgh Cancer Institute) for providing the permanent HNSCC cell lines used in this work. This work was supported by grants of the following funding bodies, Mildred-Scheel-Stiftung (Deutsche Krebshilfe), the Monika-Kutzner-Stiftung, the Werner-and-Klara-Kreitz-Stiftung and the Rudolf-Bartling-Stiftung.

References


54. Ronchetti S, Zollo O, Bruscoli S, Agostini M, Bianchini R, Nocentini G, Ayroldi E and Riccardi C: GITR, a member of the


72. GA, Fox SB, Hun C, Leek RD, Garcia JF, Harris AL, and Banham AH: Quantification of regulatory T cells enables the

75. Miller AM, Lundberg K, Ozenci V, Banham AH, Hellstrom M, Pakravan N, Hassan AT and Hassan ZM: Naturally Occurring


77. Miller AM, Lundberg K, Ozenci V, Banham AH, Hellstrom M, Egevad L and Pisa P: CD4+CD25+ regulatory T cells are enriched


